Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00268177 |
This study was designed to look at effects of salmeterol/fluticasone propionate compared to placebo on airway inflammation in patients with chronic obstructive airways disease
Condition | Intervention | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: Salmeterol/fluticasone propionate 50/500mcg Diskus |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Efficacy Study |
Official Title: | A 13-Week, Double-Blind, Parallel Group, Multi-Centre Study to Compare the Bronchial Anti-Inflammatory Activity of the Combination of Salmeterol/Fluticasone Propionate 50/500mcg Twice Daily Compared With Placebo Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
Estimated Enrollment: | 130 |
Study Start Date: | October 2002 |
Ages Eligible for Study: | 40 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |
GSK Investigational Site | |
Aalborg, Denmark, DK-9100 | |
GSK Investigational Site | |
Kobenhavn NV, Denmark, 2400 | |
Estonia | |
GSK Investigational Site | |
Tallinn, Estonia, 13419 | |
GSK Investigational Site | |
Tartu, Estonia, 51014 | |
Finland | |
GSK Investigational Site | |
Helsinki, Finland, 00029 | |
Italy, Sicilia | |
GSK Investigational Site | |
Palermo, Sicilia, Italy, 90146 | |
Lithuania | |
GSK Investigational Site | |
Kaunas, Lithuania, LT-44320 | |
GSK Investigational Site | |
Kaunas, Lithuania, LT-50009 | |
GSK Investigational Site | |
Vilnius, Lithuania, LT-08661 | |
Slovakia | |
GSK Investigational Site | |
Bratislava, Slovakia, 825 56 | |
GSK Investigational Site | |
Kosice, Slovakia, 041 90 | |
Spain | |
GSK Investigational Site | |
Madrid, Spain, 28047 | |
GSK Investigational Site | |
Caceres, Spain, 10003 | |
United Kingdom | |
GSK Investigational Site | |
London, United Kingdom, E7 8QP | |
GSK Investigational Site | |
London, United Kingdom, E2 9JX | |
GSK Investigational Site | |
Hull, United Kingdom, HU16 5JQ | |
United Kingdom, Leicestershire | |
GSK Investigational Site | |
Leicester, Leicestershire, United Kingdom, LE3 9QP | |
United Kingdom, Norfolk | |
GSK Investigational Site | |
Norwich, Norfolk, United Kingdom, NR4 7UZ | |
United Kingdom, Nottinghamshire | |
GSK Investigational Site | |
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB | |
GSK Investigational Site | |
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | SCO30005 |
Study First Received: | December 20, 2005 |
Last Updated: | December 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00268177 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency; Denmark: Danish Medicines Agency; Estonia: The State Agency of Medicine; Finland: National Agency for Medicines; Italy: The Italian Medicines Agency; Lithuania: State Medicine Control Agency - Ministry of Health; Slovakia: State Institute for Drug Control; Spain: Spanish Agency of Medicines |
Chronic Obstructive Pulmonary |
Airways salmeterol/fluticasone propionate inflammation |
Lung Diseases, Obstructive Salmeterol Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Fluticasone Inflammation Pulmonary Disease, Chronic Obstructive |
Anti-Inflammatory Agents Respiratory System Agents Neurotransmitter Agents Adrenergic beta-Agonists Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Asthmatic Agents |
Anti-Allergic Agents Adrenergic Agonists Pharmacologic Actions Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Dermatologic Agents Bronchodilator Agents |